Michael E. Hurwitz, PhD, MD

Assistant Professor of Medicine (Medical Oncology)

Clinical Interests

  • Adult
  • Urinary Bladder Neoplasms
  • Kidney Neoplasms
  • Medical Oncology
  • Prostatic Neoplasms
  • Testicular Neoplasms

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From physicians only

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Cancer Center, Yale: Prostate and Urologic Cancers Program

General Urology

Medical Oncology

Yale Medical Group

Office of Cooperative Research

Clinical Trials

Conditions Study Title
Prostate A Phase I/II Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in mCRPC
Prostate VT-464 in Patients W/Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Bladder WO29636: IMvigor 010 Study: Anti-(PD-L1) Antibody MPDL3280A Treatment vs. Versus Observation
Bladder S1314 (COXEN) with neoadjuvant therapy for localized, muscle invasive bladder cancer
Kidney, Lung, Melanoma, skin, Phase I A phase 1/2 Dose escalation and expansion study of NKTR-214 in patients with adv. or met. tumors
Melanoma, skin Study Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 Metastatic Melanoma
Prostate, Phase I EC1169-01:Phase I study of PSA Targeting Tubulysin Conjugate EC1169 in Patients with recurrent mCRPC
Prostate ARMOR3-SV: Phase 3 trial of Galeterone Compared to Enzalutamide AR-V7 M1 CRPC
Bladder, Other Urinary JVDC 05 (RANGE): Ramucirumab Plus Docetaxel in Participants With Urothelial Cancer
Bladder, Other Urinary ML29725: Expanded access program for atezolizumab in metastatic urothelial cancer
Bladder, Lung, Other Digestive Organ, Other Urinary, Stomach, Phase I Ramucirumab + Pembro with Gastric or GEJ Adenocarcinoma, NSCLC or Tcell carcinoma of urothelium
Melanoma, skin Refractory B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Exhibits B7-H3 Neoplasms
Colon, Melanoma, skin, Phase I Phase 1 Study of CM-24 (MK-6018) in Subjects with Selected Advanced or Recurrent Malignancies
Kidney, Phase I Phase 1 study of safety & pharmacology with locally advanced or metastatic solid tumors
Melanoma, skin, Phase I Varlilumab and Nivolumab in advanced refractory solid tumors
Soft Tissue, Phase I Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 & Mogamulizumab in Combinati
Bladder S1011: Standard or Extended Pelvic Lymphadenectomy in Pts to have Surgery for Invasive Bladder Canc
Bladder, Phase I Novartis BGJ398: A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic
Melanoma, skin Stand Up To Cancer

Edit this profile

Contact Info

Michael E. Hurwitz, PhD, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavilion 4

New Haven, CT 06510
View on map...
Mailing Address
PO Box 208032
New Haven, CT 06520